Trials / Unknown
UnknownNCT01250847
Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)
Phase IV Study of Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 83 (estimated)
- Sponsor
- Severance Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 35 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to assess the effects of 'Seroquel-XR' on the verbal learning ability in people with at-risk mental state (ARMS) over a 12 week period. The verbal learning ability will be indexed by delayed free recall score of CVLT(California Verbal learning Test), a standard neuropsychological verbal memory tests. The secondary objective is to assess the effects of 'Seroquel-XR' on other cognitive function and psychiatric symptoms including psychotic, anhedonic symptoms, and impulsivity. The cognitive function abilities will be measured by standard neuropsychological tests as follows; * Working memory: verbal \& spatial 2-back test * Attention: Digit Span, 3-7 CPT(Continuous Performance Test) * Executive function: WCST (Wisconsin Card Sorting Test) * Visuo-spatial ability: Rey Complex Figure Task copy * Visuomotor speed and planning: Trail making test A \& B * Verbal fluency: Controlled Oral Word Association Test(COWAT) The scales of psychiatric symptoms which will be used are as follows; * Psychotic symptoms: Scales of Prodromal scales (SOPS), Positive and negative syndrome scale (PANSS) * Anhedonia: Social Anhedonia Scale (SAS), Physical Anhedonia Scale (PAS) * Social cognition: Ambiguous Intention Hostility Questionnaire (AIHQ) * Impulsivity: Barrett Impulsivity Scale (BIS)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Quetiapine(Seroquel-XR) 50~800mg a day | The only ARMS subjects will be given 50\~800mg Seroquel-XR once daily for total of 12 weeks. |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-10-01
- Completion
- 2012-10-01
- First posted
- 2010-12-01
- Last updated
- 2011-08-19
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01250847. Inclusion in this directory is not an endorsement.